 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Investors considering a purchase of Corcept Therapeutics Inc (CORT) shares, but tentative about paying the going market price of 27.24/share, might benefit from considering selling puts among...

#36;25, Earn 20.2% Annualized Using Options

Corcept Therapeutics Incorporated (NASDAQ:CORT  Free Report)  Research analysts at Zacks Research increased their Q2 2024 EPS estimates for shares of Corcept Therapeutics in a report...

Q2 2024 EPS Estimates for Corcept Therapeutics Incorporated (NASDAQ:CORT) Lifted by Zacks Research

This is a signal that CORT's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Corcept Therapeutics (CORT, $33.62) RSI Indicator left the overbought zone on September 13, 2023

Check out John Hussman Stock Picks &raquo;

 Download GuruFolio Report of John Hussman (Updated on 09/06/2023), Check out Chuck Royce Stock Picks &raquo;

 Download GuruFolio Report of Chuck Royce...

Corcept Therapeutics Inc's Meteoric Rise: Unpacking the 36% Surge in Just 3 Months

Is Corcept Therapeutics (CORT) fairly valued? Let's delve into its financials and growth prospects to find out.Related Stocks: CORT...

Decoding Corcept Therapeutics (CORT)'s Market Value: An In-Depth Analysis

ExodusPoint Capital Management LP grew its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT  Free Report) by 35.4% during the 1st quarter, according to its most recent 13F...

ExodusPoint Capital Management LP Acquires 14,755 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT)

Swiss National Bank trimmed its holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT  Free Report) by 10.1% in the first quarter, according to its most recent 13F filing with the...

Corcept Therapeutics Incorporated (NASDAQ:CORT) Stake Decreased by Swiss National Bank

BI Asset Management Fondsmaeglerselskab A S acquired a new stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT  Free Report) during the 1st quarter, according to the company in...

BI Asset Management Fondsmaeglerselskab A S Invests $2.19 Million in Corcept Therapeutics Incorporated (NASDAQ:CORT)

Skandinaviska Enskilda Banken AB publ acquired a new position in Corcept Therapeutics Incorporated (NASDAQ:CORT  Free Report) during the first quarter, according to the company in its most...

106,100 Shares in Corcept Therapeutics Incorporated (NASDAQ:CORT) Acquired by Skandinaviska Enskilda Banken AB publ

Corcept Therapeutics: Far More Constructive With Korlym Resolve (Rating Upgrade)

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.

Watchers	2,778
52-Wk Low	$17.86
52-Wk High	$34.28

Market Cap	$2.7B
Volume (M)	1.63M
52-Wk High	$34.28
52-Wk Low	$17.86

CORT Corcept Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals